scholarly journals Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration

2017 ◽  
Vol 96 (2) ◽  
pp. e201-e212 ◽  
Author(s):  
Estefania Cobos ◽  
Sergio Recalde ◽  
Jaouad Anter ◽  
Maria Hernandez-Sanchez ◽  
Carla Barreales ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Functional Response ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Vegf Polymorphisms ◽  
Ranibizumab Treatment

scholarly journals Estimated Cases of Blindness and Visual Impairment from Neovascular Age-Related Macular Degeneration Avoided in Australia by Ranibizumab Treatment

PLoS ONE ◽  
2014 ◽  
Vol 9 (6) ◽  
pp. e101072 ◽  
Author(s):  
Paul Mitchell ◽  
Neil Bressler ◽  
Quan V. Doan ◽  
Chantal Dolan ◽  
Alberto Ferreira ◽  
...  
Keyword(s):  
Visual Impairment ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Ranibizumab Treatment

scholarly journals Roles of Three Common VEGF Polymorphisms in the Risk of Age-Related Macular Degeneration

2014 ◽  
Vol 18 (4) ◽  
pp. 245-252 ◽  
Author(s):  
Yuqing Liu ◽  
Siqing Hou ◽  
Weihua Lang ◽  
Dongshu Dai ◽  
Zhixue Wang ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Vegf Polymorphisms

scholarly journals Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration – results from the randomized, phase IIIb OCTAVE study

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Giovanni Staurenghi ◽  
Justus G. Garweg ◽  
Bianca S. Gerendas ◽  
Wayne Macfadden ◽  
Boris Gekkiev ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Comparable Group ◽  
Link Type ◽  
Age Related ◽  
Group I ◽  
Central Subfield Thickness ◽  
Phase Iiib ◽  
Group Ii ◽  
Ranibizumab Treatment

Abstract Background To evaluate the efficacy and safety of two individualized ranibizumab retreatment schemes in neovascular age-related macular degeneration. Methods Patients (N = 671) were randomized (1:1) to receive three initial monthly ranibizumab 0.5 mg injections, then retreatment guided by either best-corrected visual acuity (BCVA) loss (Group I) or BCVA loss and/or signs of disease activity on optical coherence tomography (OCT; Group II). The study was terminated prematurely and the decision to discontinue the study was made by the sponsor. Efficacy analyses were performed on patients who completed 12 months of the originally planned 24-month study. Safety analyses are presented for all safety analyzable patients. Results Of 671 randomized patients, 305 completed 12 months of the study. For the 12-month completers, baseline mean (standard deviation) BCVA and reading-center evaluated central subfield thickness (CSFT) were comparable [Group I: 60.9 (13.10) letters and 517.7(201.79) μm; Group II: 60.2 (12.21) letters and 515.3 (198.37) μm]. The change from baseline at Month 12 in BCVA was 6.7 (13.48) letters in Group I and 8.3 (13.53) letters in Group II and the change in CSFT was − 161.3 (163.48) μm and − 175.3 (170.45) μm, respectively. The mean number of ranibizumab injections was 8.2 in Group I and 8.4 in Group II. Conclusion Ranibizumab treatment resulted in visual and anatomic gains at 12 months for both retreatment strategies, with a trend in favor of OCT-guided vs BCVA loss guided retreatment. No new safety signals were seen. Trial registration www.ClinicalTrials.gov (NCT01780935). Registered 31 January 2013.

scholarly journals RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Retina ◽  
2019 ◽  
Vol 40 (9) ◽  
pp. 1673-1685 ◽  
Author(s):  
Frank G. Holz ◽  
Marta S. Figueroa ◽  
Francesco Bandello ◽  
Yit Yang ◽  
Masahito Ohji ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Treatment Naïve ◽  
Ranibizumab Treatment

scholarly journals A genetic variant in NRP1 is associated with worse response to ranibizumab treatment in neovascular age-related macular degeneration

2016 ◽  
Vol 26 (1) ◽  
pp. 20-27 ◽  
Author(s):  
Laura Lorés-Motta ◽  
Freekje van Asten ◽  
Philipp S. Muether ◽  
Dzenita Smailhodzic ◽  
Joannes M. Groenewoud ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Genetic Variant ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Ranibizumab Treatment

VEGF-Apolymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration

2013 ◽  
Vol 14 (6) ◽  
pp. 623-630 ◽  
Author(s):  
Stefano Lazzeri ◽  
Michele Figus ◽  
Paola Orlandi ◽  
Anna Fioravanti ◽  
Teresa Di Desidero ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Functional Response ◽  
Age Related Macular Degeneration ◽  
Short Term ◽  
Intravitreal Ranibizumab ◽  
Age Related
Sign in / Sign up

Export Citation Format

Share Document